TY - JOUR
T1 - Molecular dynamics simulation study of boron-nitride nanotubes as a drug carrier
T2 - From encapsulation to releasing
AU - Roosta, Sara
AU - Nikkhah, Sousa Javan
AU - Sabzali, Mehdi
AU - Hashemianzadeh, Seyed Majid
N1 - Publisher Copyright:
© The Royal Society of Chemistry 2016.
PY - 2016
Y1 - 2016
N2 - Understanding the encapsulation and release processes of drug molecules using nanocarriers is vital for the development of nanoscale drug delivery. Boron-nitride nanotubes (BNNTs) are inherently non-cytotoxic and may be superior to CNTs for utilization as biological probes and applying in biomaterial systems. In the present study, molecular dynamics (MD) simulations were utilized to investigate the encapsulation and the releasing processes of gemcitabine (GMC) as an anti-cancer drug in the interior of cells using BNNTs as a nanocarrier. According to the results of an encapsulation study, the drug molecule tended to be located inside the BNNT and stayed at its center along the length of the nanotube. For the case of the release process, results revealed that the rate of the releasing agent's entrance into the nanotube could be influenced by the presence of the drug. Herein, in addition to using fullerene (C60) as a usual structure for drug delivery, the heterofullerene (C48B12) as a new releasing agent was suggested. Interestingly, the simulations indicated that GMC could only be expelled from BNNT by C48B12 and the van der Waals interactions were the main driving force for the releasing process.
AB - Understanding the encapsulation and release processes of drug molecules using nanocarriers is vital for the development of nanoscale drug delivery. Boron-nitride nanotubes (BNNTs) are inherently non-cytotoxic and may be superior to CNTs for utilization as biological probes and applying in biomaterial systems. In the present study, molecular dynamics (MD) simulations were utilized to investigate the encapsulation and the releasing processes of gemcitabine (GMC) as an anti-cancer drug in the interior of cells using BNNTs as a nanocarrier. According to the results of an encapsulation study, the drug molecule tended to be located inside the BNNT and stayed at its center along the length of the nanotube. For the case of the release process, results revealed that the rate of the releasing agent's entrance into the nanotube could be influenced by the presence of the drug. Herein, in addition to using fullerene (C60) as a usual structure for drug delivery, the heterofullerene (C48B12) as a new releasing agent was suggested. Interestingly, the simulations indicated that GMC could only be expelled from BNNT by C48B12 and the van der Waals interactions were the main driving force for the releasing process.
UR - http://www.scopus.com/inward/record.url?scp=84957028435&partnerID=8YFLogxK
U2 - 10.1039/c5ra22945f
DO - 10.1039/c5ra22945f
M3 - Article
AN - SCOPUS:84957028435
SN - 2046-2069
VL - 6
SP - 9344
EP - 9351
JO - RSC Advances
JF - RSC Advances
IS - 11
ER -